A panoramic study of circulating tumor DNA in diffuse large B-cell lymphoma.

Ruoyun He, Wanyue Zhang, Lisha Li, Lintao Bi

Abstract readReview

In one paragraph

Review in Genes & diseases, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ruoyun HeDepartment of Hematology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China.

Wanyue ZhangThe Second Hospital of Jilin University, Changchun, Jilin 130021, China.

Lisha LiThe Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, China.

Lintao BiDepartment of Hematology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a frequently encountered aggressive form of non-Hodgkin's lymphoma, characterized by significant clinical and molecular heterogeneity. Owing to inherent limitations of traditional treatments for DLBCL, the advent of circulating tumor DNA (ctDNA) detection, coupled with the integration of multi-omics technologies, has brought about substantial advancements in the diagnosis and treatment of this disease. This review elaborates on the evolution of ctDNA detection and multi-omics integration, its applications in early diagnosis, prognostic model construction, and treatment decision-making, as well as drug resistance mechanisms, highlighting that ctDNA is a powerful tool but faces technical, biological, and clinical implementation barriers that need to be overcome for wider clinical use.

Indexed as

Circulating tumor DNADiffuse large B-cell lymphomaDynamicmonitoringLiquid biopsyPrognostic evaluation

Identifiers

PMID42891066

DOI10.1016/j.gendis.2026.102038

PMCPMC13673099

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.